Latest news with #BofASecurities
Yahoo
a day ago
- Business
- Yahoo
BofA Affirms Amplitude (AMPL) Buy Rating Hikes Price Target to $15
Amplitude, Inc. (NASDAQ:AMPL) is one of the 13 best software stocks to buy now. On June 16, BofA Securities raised its price target to $15 from $13 while reiterating a Buy rating on the stock. The adjustment follows an investor meeting where the company discussed its agentic AI product launch. one photo/ Amplitude also touted how it plans to power the next generation of AI-powered digital experiences. BofA remains confident in Amplitude's differentiated platform, which positions it to gain market share in the long term. The research firm expects the company to capitalize on the digital analytics market valued at over $50 billion. Continued execution improvements should allow Amplitude to reduce its 55% discount multiple compared to its peers in the industry. Strategic product advancements have been the company's priority, as seen by the quick uptake of the new Guides and Surveys product. The remarks come on the company delivering a 10% year-over-year revenue growth in Q1 2025 to $80 million. Annual recurring revenue also recorded a 12% growth. Amplitude, Inc. (NASDAQ:AMPL) is a digital analytics platform that helps companies understand customer behavior within their digital products. It provides tools and insights to analyze user engagement, identify patterns, and improve product design and performance. While we acknowledge the potential of AMPL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 12 Best Healthcare Stocks to Buy Now and 10 Stocks Analysts Are Upgrading Today. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Business
- Yahoo
Caris Life Sciences Announces Pricing of Initial Public Offering
IRVING, Texas, June 17, 2025 /PRNewswire/ -- Caris Life Sciences® (Caris), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the pricing of its initial public offering of 23,529,412 shares of its common stock, at a public offering price of $21.00 per share. In addition, Caris has granted the underwriters a 30-day option to purchase up to an additional 3,529,411 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on the Nasdaq Global Select Market on June 18, 2025, under the ticker symbol "CAI." The offering is expected to close on June 20, 2025, subject to customary closing conditions. BofA Securities, J.P. Morgan and Goldman Sachs & Co. LLC are acting as lead book-running managers for the offering. Citigroup is also acting as a book-running manager for the offering. TD Cowen, Evercore ISI and Guggenheim Securities are acting as additional book-running managers for the offering. BTIG and Wolfe | Nomura Alliance are acting as co-managers for the offering. A registration statement relating to these securities has been filed with and declared effective by the Securities and Exchange Commission. The offering is being made only by means of a prospectus. Copies of the prospectus, when available, may be obtained from: BofA Securities, NC1-022-02-25, 201 North Tryon Street, Charlotte, North Carolina 28255, Attention: Prospectus Department or by email: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by email: prospectus-eq_fi@ or Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West Street, New York, New York 10282 or by email: prospectus-ny@ This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Caris Life SciencesCaris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer that is actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms at scale, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies, and high-performance computing provides a differentiated platform to develop the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development. Caris was founded with the belief and vision that combining a vast set of consistently generated molecular information with robust data-driven insights could realize the potential of precision medicine for patients. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets. Caris Life Sciences Media: Corporate CommunicationsCorpComm@ Investor Relations:Narendra ChokshiSenior Vice President, Corporate Developmentnchokshi@ View original content to download multimedia: SOURCE Caris Life Sciences Sign in to access your portfolio
Axios
3 days ago
- Business
- Axios
Caris Life Sciences raises $494M in IPO
Caris Life Sciences, a cancer diagnostics and treatment biotech, raised $494 million in its IPO at $21 per share, above its previously planned $19 to $20 per share range. By the numbers: The offering values Caris at about $5.95 billion, based on outstanding shares, lower than its 2021 valuation of $7.83 billion. It is expected to begin trading Wednesday on the Nasdaq under CAI. BofA Securities, JPMorgan, Goldman Sachs and Citigroup are leading. Catch up quick: Caris set terms June 9, aiming to sell 23.5 million shares for $16 to $18 but raised its range on Monday, planning to raise $470.6 million at the high end. Caris last raised in 2021, snagging $830 million in a growth equity round led by Sixth Street. The latest: The company, with 1,700 employees, reported a net loss of $127 million on $120.9 million in revenue during Q1 of this year. That's an improvement from a net loss of $134.1 million on $80.7 million in revenue over the same period a year ago. Caris says it has more than 90 payer contracts and over 100 biopharma partners. Company founder and chairman David D. Halbert is slated to own nearly 44% of the company based on a public offering price of $19.50 per share, per the company's updated filing. State of play: Caris' IPO signals the public markets may be reopening to biotech companies, which have grappled with various headwinds this year, spooking generalist investors.
Yahoo
4 days ago
- Business
- Yahoo
Caris Life Sciences Announces Pricing of Initial Public Offering
IRVING, Texas, June 17, 2025 /PRNewswire/ -- Caris Life Sciences® (Caris), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the pricing of its initial public offering of 23,529,412 shares of its common stock, at a public offering price of $21.00 per share. In addition, Caris has granted the underwriters a 30-day option to purchase up to an additional 3,529,411 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on the Nasdaq Global Select Market on June 18, 2025, under the ticker symbol "CAI." The offering is expected to close on June 20, 2025, subject to customary closing conditions. BofA Securities, J.P. Morgan and Goldman Sachs & Co. LLC are acting as lead book-running managers for the offering. Citigroup is also acting as a book-running manager for the offering. TD Cowen, Evercore ISI and Guggenheim Securities are acting as additional book-running managers for the offering. BTIG and Wolfe | Nomura Alliance are acting as co-managers for the offering. A registration statement relating to these securities has been filed with and declared effective by the Securities and Exchange Commission. The offering is being made only by means of a prospectus. Copies of the prospectus, when available, may be obtained from: BofA Securities, NC1-022-02-25, 201 North Tryon Street, Charlotte, North Carolina 28255, Attention: Prospectus Department or by email: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by email: prospectus-eq_fi@ or Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West Street, New York, New York 10282 or by email: prospectus-ny@ This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Caris Life SciencesCaris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer that is actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms at scale, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies, and high-performance computing provides a differentiated platform to develop the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development. Caris was founded with the belief and vision that combining a vast set of consistently generated molecular information with robust data-driven insights could realize the potential of precision medicine for patients. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets. Caris Life Sciences Media: Corporate CommunicationsCorpComm@ Investor Relations:Narendra ChokshiSenior Vice President, Corporate Developmentnchokshi@ View original content to download multimedia: SOURCE Caris Life Sciences
Yahoo
4 days ago
- Business
- Yahoo
Caris Life raises $494 million in US IPO
(Reuters) -Caris Life Sciences raised $494.1 million in its Nasdaq initial public offering, the cancer diagnostic firm said on Tuesday, amid a rebound in the IPO market. Investors have shown renewed interest in U.S. IPOs in recent weeks, following a prolonged slowdown triggered by uncertainties over President Donald Trump's tariff policies. The recent surge in listing activity and strong market debuts of virtual healthcare providers Omada and Hinge Health have encouraged other companies in the sector to move forward with their listing plans. The Irving, Texas-based company sold roughly 23.5 million shares, at $21 apiece, above its increased marketed price range of between $19 and $20. Caris is an artificial intelligence-based precision medicine firm that helps diagnose cancer through tumor profiling and blood-based cancer diagnostics. Founded in 2008 by CEO David Halbert, Caris generates revenue mainly from its tissue-based molecular profiling, which helps determine the appropriate cancer therapy for each case. Caris will start trading on the Nasdaq on Wednesday under the symbol "CAI". BofA Securities, J.P. Morgan, Goldman Sachs and Citigroup are the lead underwriters. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
